Autobahn Plans to Start Clinical Development of AMN Candidate ABX-002 in 2021
News
Autobahn Therapeutics has successfully completed a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plan for its therapy ABX-002, a thyroid hormone ... Read more